{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:26:17Z","timestamp":1747178777130,"version":"3.40.5"},"reference-count":134,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2022,7,24]]},"DOI":"10.1080\/14656566.2022.2097868","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T08:44:47Z","timestamp":1657010687000},"page":"1305-1323","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacotherapy for Alzheimer\u2019s disease: what\u2019s new on the horizon?"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-6816","authenticated-orcid":false,"given":"Rita","family":"Khoury","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Clinical Psychology, St. Georges Hospital University Medical Center, Beirut, Lebanon"},{"name":"Faculty of Medicine, University of Balamand, Beirut, Lebanon"},{"name":"Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Gallop","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-1275","authenticated-orcid":false,"given":"Noam","family":"Grysman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-3047","authenticated-orcid":false,"given":"Jiaxi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-3931","authenticated-orcid":false,"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, St Louis University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"cit0001","unstructured":"Alzheimer\u2019s Association Facts and Figures. Alzheimer\u2019s association; 2021."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1790530"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2019.100005"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-32-9721-0_3"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-017-0499-x"},{"issue":"2","key":"cit0007","first-page":"109","volume":"4","author":"Cummings J","year":"2017","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"4","key":"cit0008","first-page":"398","volume":"8","author":"Cummings J","year":"2021","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1468"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1126\/science.7046051"},{"key":"cit0011","unstructured":"Yang. Inhibition of Cholinesterase by Octohydroaminoacri- dine Succinate [Master\u2019s Thesis]. Changchun, Jilin, China: Jilin University; 2007."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afx045"},{"key":"cit0013","unstructured":"NCT03283059. Octohydroaminoacridine succinate tablet for mild-to-moderate Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03283059?cond=NCT03283059&draw=2&rank=1"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0216-x"},{"key":"cit0015","first-page":"1105","volume":"40","author":"Kong LN","year":"2005","journal-title":"Yao xue xue bao = Acta pharmaceutica Sinica"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00678-3"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01268-1"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00795-7"},{"key":"cit0019","unstructured":"NCT05114499. Efficacy and safety of donepezil and sodium oligomannate in patients with mild to moderate Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05114499?term=NCT05114499&draw=2&rank=1"},{"key":"cit0020","unstructured":"NCT04520412. A study of sodium oligomannate (GV-971) in participants with mild to moderate Alzheimer\u2019s disease (GREEN MEMORY). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04520412?term=NCT04520412&draw=2&rank=1"},{"key":"cit0021","unstructured":"NCT04229927. BPDO-1603 intervention trial in patients with moderate-to-severe Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04229927?term=NCT04229927&draw=2&rank=1"},{"issue":"8","key":"cit0022","first-page":"448","volume":"35","author":"Cruz MP","year":"2010","journal-title":"Pharm Ther"},{"issue":"3","key":"cit0023","first-page":"107","volume":"44","author":"Alamo C","year":"2016","journal-title":"Actas espanolas de psiquiatria"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00111-1"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830050084013"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02867-8"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2018.05.033"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(91)90051-K"},{"key":"cit0029","unstructured":"NCT03116126. Noradrenergic add-on therapy with guanfacine (NorAD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03116126?term=NCT03116126&draw=2&rank=1"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.3112re3"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12425-w"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-9406"},{"key":"cit0033","unstructured":"NCT04842552. Effect of Hydralazine on Alzheimer\u2019s Disease (EHSAN)."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3897\/folmed.63.e53060"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-017-0547-2"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01688"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.721216"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.775034"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2013.10.042"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020537"},{"key":"cit0041","unstructured":"NCT04570085. Effect of CAFfeine on cognition in Alzheimer\u2019s disease (CAFCA). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04570085?term=NCT04570085&draw=2&rank=1"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1002\/alz.046189"},{"key":"cit0043","unstructured":"NCT03721705. Renew NCP-5 for the treatment of mild cognitive impairment due to Alzheimer\u2019s Disease (AD) or mild dementia of the Alzheimer\u2019s type. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03721705"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X15666170116143743"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2009.11.2\/pdavies"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3537-10.2010"},{"issue":"7","key":"cit0047","first-page":"672","volume":"10","author":"Schmidt AM","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.348"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140741"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0181-2"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"cit0053","unstructured":"NCT03887455. A study to confirm safety and efficacy of lecanemab in participants with early alzheimer\u2019s disease (clarity AD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03887455"},{"key":"cit0054","unstructured":"NCT04468659. AHEAD 3-45 study: a study to evaluate efficacy and safety of treatment with lecanemab in participants with preclinical Alzheimer\u2019s disease and elevated amyloid and also in participants with early preclinical Alzheimer\u2019s disease and intermediate amyloid. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468659?term=NCT04468659&draw=2&rank=1"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110977"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0559-z"},{"issue":"1","key":"cit0058","first-page":"3","volume":"8","author":"Klein G","year":"2021","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01369-8"},{"key":"cit0060","unstructured":"Taylor NP. UPDATE: roche dismisses early filing chatter for its Alzheimer\u2019s drug as speculation, remains focused on phase 3 trial; 2021. Available from: https:\/\/www.fiercebiotech.com\/biotech\/roche-to-seek-early-fda-approval-for-alzheimer-s-drug-following-lilly-through-door-blown"},{"key":"cit0061","unstructured":"Buntz B. Roche\u2019s amyloid-targeting gantenerumab wins breakthrough therapy designation for Azheimer\u2019s. Available from: https:\/\/www.drugdiscoverytrends.com\/roches-amyloid-targeting-gantenerumab-wins-breakthrough-therapy-designation-for-azheimers"},{"key":"cit0062","unstructured":"NCT03444870. Efficacy and safety study of gantenerumab in participants with early alzheimer\u2019s disease (AD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03444870"},{"key":"cit0063","unstructured":"NCT03443973. Safety and efficacy study of gantenerumab in participants with early Alzheimer\u2019s Disease (AD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443973"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1159\/000511506"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181cb577a"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.09.224"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"cit0069","unstructured":"NCT02760602. A study of Solanezumab (LY2062430) in participants with prodromal Alzheimer\u2019s disease (ExpeditionPRO). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02760602"},{"key":"cit0070","unstructured":"NCT02008357. Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008357"},{"issue":"1","key":"cit0071","first-page":"e12112","volume":"7","author":"Lowe SL","year":"2021","journal-title":"Alzheimers Dementia"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"cit0073","unstructured":"NCT04437511. A study of donanemab (LY3002813) in participants with early Alzheimer\u2019s disease (TRAILBLAZER-ALZ 2). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04437511"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4742-11.2012"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200134"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005550"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0424-5"},{"key":"cit0078","unstructured":"Hoffman M. Crenezumab phase 3 CREAD trials in Alzheimer disease discontinued by Roche; 2019."},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12109"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2385"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e2348"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000364"},{"key":"cit0083","unstructured":"NCT02080364. Evaluation of the efficacy and safety of azeliragon (TTP488) in patients with mild alzheimer\u2019s disease (STEADFAST). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02080364"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1258"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12645"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706441"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812840"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1021\/cn500148z"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00025"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0013-z"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3245935"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170560"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1719066"},{"key":"cit0095","unstructured":"NCT03446001. Safety and efficacy of trx0237 in subjects with Alzheimer\u2019s disease followed by open-label treatment. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03446001"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1002\/alz.045331"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2014.09.013"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2011.05.017"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00554.x"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3310"},{"key":"cit0101","unstructured":"NCT03486938. Study of AGB101 in mild cognitive impairment due to Alzheimer\u2019s disease (HOPE4MCI). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03486938?term=NCT03486938&draw=2&rank=1"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2014.11.011"},{"key":"cit0103","first-page":"463","volume":"8","author":"Lahmy V","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"cit0104","first-page":"1","volume":"12","author":"Voges O","year":"2015","journal-title":"Innov Clin Neurosci"},{"issue":"1","key":"cit0105","doi-asserted-by":"crossref","first-page":"e12013","DOI":"10.1002\/trc2.12013","volume":"6","author":"Hampel H","year":"2020","journal-title":"Alzheimers Dement"},{"key":"cit0106","unstructured":"NCT03790709. ANAVEX2-73 for treatment of early Alzheimer\u2019s disease."},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-200250"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau3333"},{"key":"cit0109","unstructured":"Cicinelli C. Cortexyme reports GAIN trial data demonstrated relationship between reduction of P. gingivalis Infection and Slowing of Alzheimer\u2019s Disease Progression. Available from: https:\/\/www.cortexyme.com\/cortexyme-reports-gain-trial-data-demonstrated-relationship-between-reduction-of-p-gingivalis-infection-and-slowing-of-alzheimers-disease-progression\/"},{"key":"cit0110","unstructured":"Cortexyme. cortexyme announces clinical hold on atuzaginstat\u2019s investigational new drug application. Available from: https:\/\/www.cortexyme.com\/cortexyme-announces-clinical-hold-on-atuzaginstats-investigational-new-drug-application"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.06.014"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2021-0022"},{"key":"cit0113","unstructured":"NCT04669028. A phase 3 study of NE3107 in Alzheimer\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04669028?term=NE3107&cond=alzheimer&draw=2&rank=1"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-141074"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.747284"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1002\/alz.038787"},{"issue":"14","key":"cit0117","volume":"07","author":"Henderson S","year":"2018","journal-title":"Alzheimers Dement"},{"key":"cit0118","unstructured":"NCT04187547. A phase III multi regional clinical trial (mrct) of tricaprilin in mild to moderately severe probable alzheimer\u2019s disease with optional open label extension. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04187547"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00424-9"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0082-1"},{"key":"cit0121","unstructured":"program AA. Available from: https:\/\/www.fda.gov\/drugs\/information-health-care-professionals-drugs\/accelerated-approval-program."},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3126"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12213"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00557-x"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180903"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1948010"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180766"},{"key":"cit0128","first-page":"Cd002039","volume":"3","author":"Darbyshire J","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0129","unstructured":"Park A. The story behind the first AIDS drug; 2017. Available from: https:\/\/time.com\/4705809\/first-aids-drug-azt"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0529-5"},{"issue":"1","key":"cit0131","doi-asserted-by":"crossref","first-page":"e12009","DOI":"10.1002\/trc2.12009","volume":"6","author":"Cole MA","year":"2020","journal-title":"Alzheimers Dement"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.03.035"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-05542-4_2"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi6401"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2022.2097868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T05:19:33Z","timestamp":1700803173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2022.2097868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,7,24]]}},"alternative-id":["10.1080\/14656566.2022.2097868"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2022.2097868","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}